FirstWord

The biotech will advance its ruvonoflast into a Phase III peripheral artery disease trial after positive mid-stage inflammation data.

Tectora is advancing oral therapies within the immunology and inflammation (I&I) disease space.

Hyrnuo was initially cleared last year as a second-line treatment for locally advanced or metastatic non-squamous non–small-cell lung cancer in patients whose tumours have HER2 TK domain activating mutations.

Bristol Myers Squibb and Bain Capital have poured over $400 million into Beeline and its pipeline of immunology assets, licensed from the US pharma.

Solstice Oncology launched in February, licensing the anti–CTLA-4 antibody porustobart from Harbour BioMed.

Initial results from RESTORE-PV show DISC-3405 increased hepcidin and lowered serum iron, translating to controlled hematocrit, reduced phlebotomy, and improved symptoms in PV patientsDISC-3405 is the...

DIEPPE, New Brunswick, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Hexiris Ophthalmics, a physician-founded developer of interventional glaucoma technologies, today announced a fall program spanning five major...

PD-1/VEGF bispecifics, GSK's ris-rez, and Cullinan and Otsuka's zipalertinib will feature among this weekend's World Conference on Lung Cancer in Seoul.

IRVINE, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced an oral presentation highlighting the long-term safety and efficacy of tegopru...

SAN DIEGO, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent ...